Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results

被引：1

作者：

Liu, Joyce ^{[1
]}

O'Malley, David ^{[2
,3
]}

Van Nieuwenhuysen, Els ^{[4
]}

Moore, Kathleen ^{[5
]}

Hamilton, Erika ^{[6
]}

Yeku, Oladapo ^{[7
]}

Bouberhan, Sara ^{[7
]}

Hou, June ^{[8
]}

Schroeder, David ^{[9
]}

Wang, Bin ^{[10
]}

Yoo, Suk-Young ^{[10
]}

Govindraj, Shilpa ^{[11
]}

Brouwer-Visser, Jurriaan ^{[12
]}

Peterman, Mary ^{[13
]}

Schmidt, Tamara ^{[13
]}

Barnes, Brigid ^{[13
]}

Lowy, Israel ^{[13
]}

Uldrick, Thomas ^{[13
]}

Miller, Elizabeth ^{[13
]}

O'Cearbhaill, Roisin ^{[14
,15
]}

机构：

[1] Dana Farber Canc Inst, Div Gynecol Oncol, Boston, MA 02115 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] James Canc Ctr, Div Gynecol Oncol Obstet & Gynecol, Columbus, OH USA

[4] Leuven Canc Inst, Gynaecol & Obstet, Leuven, Belgium

[5] Univ Oklahoma, Sarah Cannon Res Inst, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[6] Tennessee Oncol Breast & Gynecol Canc Res, Sarah Cannon Res Inst, Nashville, TN USA

[7] Massachusetts Gen Hosp, Gynecol Oncol Program, Boston, MA USA

[8] Columbia Univ, Med Ctr, Div Gynecol Oncol, New York, NY USA

[9] Grand Hop Charleroi, Serv Oncol Hematol, Charleroi, Belgium

[10] Regeneron Pharmaceut Inc, Biostat, Tarrytown, NY USA

[11] Regeneron Pharmaceut Inc, Global Patient Safety, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Precis Med, Tarrytown, NY USA

[13] Regeneron Pharmaceut Inc, Oncol Clin Dev, Tarrytown, NY USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Weill Cornell Med Coll, Gynecol Med Oncol Serv, New York, NY USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO011LBA

引用

页码：A9 / A10

页数：2

共 50 条

[31] Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC).
Wang, Siyang
Huang, Xiaoming
Bai, Yu-Xian
Yuan, Ying
Li, Jian
Wang, Zuobai
Wei, Chenlu
Li, Xin
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).
Winer, Ira Seth
Shields, Anthony Frank
Yeku, Oladapo O.
Liu, Joyce F.
Peterman, Mary Jane
Yoo, Suk Young
Lowy, Israel
Yama-Dang, N. Alice
Goncalves, Priscila Hermont
Kroog, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer
Zhang, Q.
Feng, M.
Chen, L.
Yan, L.
Huang, Y.
ANNALS OF ONCOLOGY, 2021, 32 : S795 - S795
[34] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
Oaknin, A.
Tinker, A. V.
Gilbert, L.
Samouelian, V.
Mathews, C. A.
Brown, J.
Guo, W.
Danaee, H.
Im, E.
Sabatier, R.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 6 - 6
[35] Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
Hanker, L. C.
Oaknin, A.
Tinker, A.
Gilbert, L.
Samouelian, V
Mathews, C.
Brown, J.
Guo, W.
Danaee, H.
Im, E.
Sabatier, R.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E220 - E220
[36] Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Hamanishi, Junzo
Mandai, Masaki
Ikeda, Takafumi
Minami, Manabu
Kawaguchi, Atsushi
Murayama, Toshinori
Kanai, Masashi
Mori, Yukiko
Matsumoto, Shigemi
Chikuma, Shunsuke
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Yamaguchi, Ken
Ueda, Akihiko
Hosoe, Yuko
Morita, Satoshi
Yokode, Masayuki
Shimizu, Akira
Honjo, Tasuku
Konishi, Ikuo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4015 - +
[37] COMBINATION OF RHIL-7-HYFC AND ANTI-PD-L1XCD3ε BISPECIFIC ANTIBODY ENHANCES ANTITUMOR RESPONSE IN MICE
Park, Sujeong
Kim, Ji-Hae
Kang, Yeon-Woo
Lee, Kun-Joo
Moon, Dain
Tae, Nara
Park, Yunji
Kim, Dae Hee
Lee, Byung Ha
Choi, Donghoon
Yang, Se Hwan
Lee, Seung-Woo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A273 - A274
[38] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update
Segal, Neil Howard
Girda, Eugenia
Sohal, Davendra
Lakhani, Nehal J.
Olszanski, Anthony J.
Fong, Lawrence
Han, Hyunsil
Casey, Kerry A.
Li, Siyu
Ganguly, Samit
Seebach, Frank A.
Mathias, Melissa Divya
Pelster, Meredith
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS239 - TPS239
[39] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Curigliano, Giuseppe
Gelderblom, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629
[40] Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial
Jiang, Y-F.
Bei, W-X.
Wang, L.
Xu, C.
Lu, N.
Liang, H.
Ke, L-R.
Ye, Y-F.
Fang, T.
He, S.
Dong, S-H.
Liu, Q.
Zhang, C.
Xia, W.
Zhao, C.
Xie, C.
Liu, G.
Xiang, Y-Q.
ANNALS OF ONCOLOGY, 2024, 35 : S633 - S634

← 1 2 3 4 5 →